The MEKK3/MEK5/ERK5 signaling axis is required for cardiovascular development in vivo.
Mariscal, Nava, & Hernandez, 2005) . Endothelial cells express tight, adherens, and gap junctions (Dejana, Corada, & Lampugnani, 1995) .
These have been demonstrated to vary in isoform expression depending on their anatomical location. Tight junctions located within the brain microvasculature contain significantly higher levels of claudin 5 than in the glomerular vasculature, reflecting the difference in permeability between the vascular beds (Gunzel & Yu, 2013) . Zonula occludens-1 (ZO-1) is a tight junction protein, which has recently been shown to regulate adherens junctions, angiogenesis, and endothelial barrier formation (Tornavaca et al., 2015) . The endothelial barrier is altered in several diseases including peripheral edema (Dong, Li, Li, Shetty, & Fu, 2016) , stroke, multiple sclerosis, and neurodegenerative diseases (Shi et al., 2016) . In these conditions, changes in endothelial permeability allow water and solutes to permeate to underlying tissues, which leads to infiltration of immune cells (Shi et al., 2016) . It is becoming apparent that anti-cancer drugs are able to induce changes in endothelial permeability, which could be an initiating event in druginduced cardiotoxicity (Cross et al., 2015; Dong et al., 2016; Wolf & Baynes, 2006) . We have recently shown that the anti-cancer drugs doxorubicin and trastuzumab (Herceptin) can adversely affect cardiac microvascular endothelial tight junction formation leading to increased drug permeability (Wilkinson, Sidaway, & Cross, 2016) .
ERK5 has been shown to be activated by a number of growth factors in a range of cell types (Nithianandarajah-Jones et al., 2012) . We have previously shown that in endothelial cells, VEGF stimulates ERK5 activity leading to increased cell survival (Roberts, Holmes, Muller, Cross, & Cross, 2010) . Recent data have shown that vasoprotective drugs such as statins, which inhibit 3-hydroxy-3-methyl-glutarylcoenzyme A reductase (HMG-CoA reductase) can also activate ERK5 in endothelial cells (Ohnesorge et al., 2010) . In addition to their ability to lower LDL-cholesterol, statins have several pleiotropic effects such as cardioprotection, however, the mechanism behind this is not yet fully understood (Chen et al., 2013; Henninger et al., 2012; Wang, Liu, & Liao, 2008) . Statins competitively inhibit HMG-CoA reductase (Stancu & Sima, 2001 ) preventing the production of cholesterol as well as isoprenoid intermediates such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphates (GGPP) (Sen-Banerjee et al., 2005) . The ability of statins to ameliorate drug-induced cardiovascular toxicity has recently been demonstrated in animal models, with cardioprotective effects attributed to effects on cardiomyocytes (Henninger et al., 2015; Yoshida, Shiojima, Ikeda, & Komuro, 2009 ).
Here, we report that statins activated ERK5 in human cardiac microvascular endothelial cells and that this activation results in an increase in tight junction formation and decreased permeability; statins can ultimately protect against doxorubicin injury of endothelial cells, which may contribute to the cardioprotective effects of these drugs.
| MATERIALS AND METHODS

| Cell culture
Human cardiac microvascular endothelial cells (HCMECs, C12285), human dermal microvascular endothelial cells (HDMECs, C-12212), human coronary artery endothelial cells (HCAECs, C-12221), human brain microvascular endothelial cells (HBMECs, C-12287), human umbilical vein endothelial cells (HUVECs, C-12205) were purchased from PromoCell (Heidelberg, Germany) and cultured as described previously (Wilkinson et al., 2016) . A2780 cells were routinely cultured in RPMI 1640 medium (61870044, Gibco) supplemented with 10% (v/v) FCS. BT474 cells were routinely cultured in DMEM medium (D6429, Sigma, Poole, UK) supplemented with 10% (v/v) FCS.
Cells were incubated at 37°C in humidified air containing 5% (v/v) CO 2 .
| Cell stimulation and preparation of cell lysates
HCMECs were grown to confluence over 6 days in FGM with changes every 2-3 days, before addition of drugs. Simvastatin (S6196 purchased from Selleck Chemicals) was diluted to 0.3 μM in EBM supplemented with 1% (v/v) FCS and then added to cells for 6 hr either alone or as a pre-incubation before addition of doxorubicin (S1208, Selleck Chemicals) diluted to 0.1 μM for a further 6 hr. BIX02189 (S1531, Selleck Chemicals) diluted to 1 μM was added 30 min prior to simvastatin treatment.
Cells were washed in ice-cold DPBS on ice followed by addition of RIPA (20 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM EDTA, 10% [w/v] glycerol, 1% [v/v] Triton X-100; 1 mM Na 3 VO 4 ; 10 μg/ml Aprotinin; 10 μg/ml Leupeptin; 10 μg/ml Pepstatin A; 1 mM PMSF; 0.5% [v/v] SDS; and 0.5% [v/v] sodium deoxycholate) lysis buffer. Lysates were centrifuged (17,000g for 20 min at 4°C) before diluting in LDS sample buffer (Invitrogen, Paisley, UK) containing 2-mercaptoethanol (Sigma, Poole, UK) and denaturing at 90°C for 5 min.
| Cell fractionation
Cellular fraction was performed using a Thermo Scientifc subcellular protein fractionation kit (78840). In brief, cells were harvested with trypsin-EDTA and centrifuged [500g for 5 min]. All buffers contain the protease inhibitor cocktail provided with the kit. The cell pellet was washed in ice cold PBS and centrifuged [500g for 5 min]. The cell pellet was resuspended in cytoplasmic extraction buffer (CEB) and incubated on ice for 10 min. Lysates were centrifuged [500g for 5 min] and the supernatant transferred to a new tube for the cytoplasmic fraction.
The pellet was resuspended in membrane extraction buffer (MEB) and incubated on ice for 10 min. Lysates were centrifuged [3,000g for 5 min] and the supernatant transferred to a new tube for the membrane fraction. The pellet was resuspended in nuclear extraction buffer (NEB) and incubated on ice for 30 min. Lysates for centrifuged [5,000g for 5 min] and the supernatant transferred to a new tube as the nuclear fraction. All fractions were diluted with LDS sample buffer containing 2-mercaptoethanol and denatured at 90°C for 5 min.
| Western blot and immunoprecipitation
For immunoprecipitation, lysates were incubated with ERK5 (2 μg/ml, #AF2848, R&D systems) or control IgG (2 μg/ml, goat) and protein G agarose. Lysates were separated by SDS-PAGE on 8% Tris-glycine gels 
| Trans-endothelial electrical resistance (TEER) assay
HCMECs were plated onto ThinCerts™ 0.4 µm translucent (12-well; Greiner, UK) and grown to confluence over 6 days. Resistance was measured using a Millicell ERS-2 volt-ohm meter (Millipore) and multiplied by the surface area of the insert to determine the TEER. 
| Viability assay
HCMECs, A2780s, and BT474s were plated on 96-well gelatin-coated plates and maintained at sub confluence for 24 hr. Cells were preincubated with 0.3 μM simvastatin before addition of doxorubicin (30-0.001 μM) for 72 hr. Cells were lysed in Cell Titer Glo® (Promega, UK) as described previously (Wilkinson et al., 2016) .
| Biochemical addback procedure
HCMECs were cultured as described previously before addition of Squalene (#S3626), cholesterol (#C4951), mevalonolactone (#M4667), geranylgeranyl pyrophosphate (GGPP, #G6025), and farnesyl pyrophosphate ammonium salt (FPP, #F6892) (purchased from Sigma, Poole, UK), for 24 hr.
| Quantitative real-time PCR (qRT-PCR) analysis
Total RNA was extracted from a range of endothelial cells and liver tissue using the RNAeasy kit following the manufacturer's instructions (Qiagen, Crawley, UK). cDNA synthesis was performed by reverse transcription of 1 μg total RNA as previously described (Wilkinson et al., 2016) . Primers: SLCO1B1 forward 5′ TTGGAGCTTGGTGGCT-TAAT 3′; SLCO1B1 reverse 5′ CCAGCACATGCAAAGACAGT 3′.
qRT-PCR was performed as described previously (Wilkinson et al., 2016) . Cycle threshold (C T ) values were determined for each mRNA sample and compared to the GAPDH control to determine gene expression changes using the comparative C T (2 −ΔΔCT ) method (Livak & Schmittgen, 2001 ).
| Statistical significance
This was performed using a one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test using SPSS software. Significant differences between control and test groups were evaluated with *p values ≤0.05 and **p values ≤0.01, indicated on the graphs. Error bars in graphs and histograms denote ± s.d. (standard deviation).
3 | RESULTS
| Endothelial tight junction formation is dependent on ERK5
Mouse ERK5 knockout studies have suggested a role for ERK5 in preserving vascular integrity (Hayashi et al., 2004) . Intercellular tight junctions are critical for endothelial cell barrier formation and regulation of paracellular diffusion (Tornavaca et al., 2015) . We (Wegener & Seebach, 2014) . Treatment with ERK5 siRNA resulted in a significant decrease in TEER indicating increased permeability ( Figure 1d ). Taken together, these data suggest that ERK5 regulates endothelial tight junction formation and paracellular permeability.
We have previously shown that the cardiotoxic drug doxorubicin is able to disrupt tight junction formation in HCMECs resulting in increased permeability (Wilkinson et al., 2016) . We used adenoviral 
| Statins induce ERK5 activation in HCMECs
We have previously reported that VEGF is able to activate ERK5 in endothelial cells and regulate endothelial cell survival (Roberts et al., 2010 Le et al., 2014) . We were interested in determining the ability of statins to activate ERK5 in HCMECs. We initially utilized activation whereas treatment with cell permeable FPP had no effect (Figure 4b ). Taken together, these data suggest that simvastatin activates ERK5 by suppressing the isoprenylation of proteins via GGPP. To further confirm the role of geranylgeranylation we utilized the geranylgeranyltransferase-I inhibitor GGTI-298 (Vogt, Qian, McGuire, Hamilton, & Sebti, 1996) . This inhibitor activated ERK5 in HCMECs after 3 hr preincubation (Figure 4c ). Furthermore, this inhibitor also stimulated tight junction formation ( Figure 4d ) and inhibited permeability in the HCMECs (Figure 4e ).
| Statins stimulate endothelial tight junction formation and decreased permeability via ERK5
Our initial data showed that constitutive activation of ERK5 can lead to increased endothelial tight junction formation and decreased permeability (Figure 2a-c) . Statins have been shown to stimulate tight junction formation in human pulmonary artery endothelial cells (Chen et al., 2014) and rat brain endothelial cells (Morofuji et al., 2010) . We were interested in determining if statins were also able to stimulate tight junction formation in an ERK5 Western blotting (Figure 5b) . Furthermore, the apparent increase We have demonstrated that simvastatin significantly decreased endothelial permeability. This decrease in permeability was prevented by pretreatment with BIX02189 (Figure 5c,d ). These data suggest that simvastatin regulated ERK5 activity leads to increased tight junction formation and reduced permeability in HCMECs. We next investigated the potential interaction between ZO-1 and ERK5 following simvastatin treatment. Immunoprecipitation of ERK5 following simvastatin treatment for 6 hr resulted in co-precipitation of ZO-1 (Figure 5e,f) indicating that ERK5 and ZO-1 can interact following simvastatin treatment.
| Statin treatment prevents doxorubicin effects on tight junctions and cell permeability in HCMECs
Statin treatment has been shown to reduce cardiotoxicity associated with doxorubicin treatment in vivo using rodent models (Henninger et al., 2015) . We have already shown that adenoviral mediated overexpression of ERK5 in HCMECs can stimulate tight junction formation and overcome the effects of doxorubicin in HCMECs (Figure 2a-c) . Considering that statins are able to activate ERK5 leading to increased tight junction formation, we determined the potential for statin pretreatment to overcome the adverse effect of doxorubicin on HCMECs. Pre-treatment with simvastatin prevented doxorubicin-induced disruption in tight junction formation (Figure 6a ) and the concomitant increase in HCMEC (Figure 6b ).
| Statin treatment stimulates ERK5 translocation to the plasma membrane in HCMECs
Activation of ERK5 by phosphorylation on Thr 218 /Tyr 220 residues in the kinase domain is thought to result in a conformational change that disrupts a nuclear export signal allowing translocation of ERK5 to the nucleus (Gomez, Erazo, & Lizcano, 2016; Kondoh, Terasawa, Morimoto, & Nishida, 2006) and regulation of MEF2 mediated gene expression (Kato et al., 1997) . Analysis of ERK5 translocation by immunofluorescence revealed that in HCMECs, simvastatin stimulated significant ERK5 translocation to the plasma membrane, which appeared to show a degree of co-localization with ZO-1 (Figure 7 ).
This co-localization was maintained in the presence of doxorubicin, but 
| DISCUSSION
Endothelial tight junctions maintain vascular integrity and regulate paracellular transport of molecules. In this study, we show that ERK5
regulates the tight junction adaptor protein ZO-1 in endothelial cells. Hayashi et al., 2004; Wang et al., 2005; Yang et al., 2000) .
The use of siRNA mediated gene silencing of ERK5 and overexpression of ERK5 in HCMECs revealed that ERK5 regulates the tight junction associated protein ZO-1 and cell permeability (Figures 1 and 2 ). This finding was further supported by the increase in permeability observed with the MEK5 inhibitor BIX02189 (Figure 5c,d ). Gene knockout of ZO-1 is embryonically lethal at E9.5-10.5 with embryos displaying defective angiogenesis (Katsuno et al., 2008) . Recent data analyzing ZO-1 function in endothelial cells has shown that ZO-1 is required for endothelial cell barrier formation and adherens junction formation (Tornavaca et al., 2015) . Our data provide a novel link to explain why loss of ERK5 results in disrupted vascular integrity and increased permeability in vivo.
Statins have been reported to stimulate a number of pleiotropic effects in endothelial cells independent of a reduction in serum cholesterol levels (Liao, 2005; Wolfrum, Jensen, & Liao, 2003) . This vascular effect has been attributed in part to stimulation of and also lead to increased cytosolic localization and activation of Rho, Rac, and Cdc42 (Xiao, Qin, Ping, & Zuo, 2013) . Another report has shown that simvastatin treatment of bovine aortic endothelial cells (BAECs) can lead to increased activation of Rac (Kou, Sartoretto, & Michel, 2009) . Our data show that statin activation of ERK5 in HCMECs requires MEKK3 (Figure 3e ). It is plausible reflect differential uptake of the drugs into HCMECs as lipophilic statins can be absorbed by passive diffusion through cell membranes (Schachter, 2005) , whereas hydrophilic statins, such as rosuvastatin, have been shown to utilize the organic anion transporters (OAT) such as OATP1B1 encoded by the SLCO1B1 gene, which is highly expressed in hepatocytes (Niemi, Pasanen, & Neuvonen, 2011 Figure S2) . Analysis of statin uptake into different tissues in rodents has shown that the hydrophilic pravastatin inhibited sterol synthesis by 90% in the liver and ileum of rodents but less than 14% in kidney, spleen, adrenal, testis, prostate, and brain, whereas the lipophilic statins lovastatin and simvastatin inhibited this process in all tissues (Koga et al., 1990) .
Recent studies in mice have shown that pretreatment with statins can protect against doxorubicin-induced cardiotoxicity (Yoshida et al., 2009 ). This effect was attributed to direct effects on cardiomyocytes in a Rac-dependent manner. Our data would suggest that the protective effect of statins can also occur at the level of the cardiac microvasculature via activation of ERK5 and increased tight junction formation with a concomitant decrease in cellular permeability of doxorubicin ultimately reducing exposure of cardiomyocytes to this drug. A clinical study in female breast cancer patients has shown that simultaneous use of statins and doxorubicin resulted in reduced heart failure compared with doxorubicin alone (Seicean, Seicean, Plana, Budd, & Marwick, 2012) . Analysis of the effect of simvastatin on viability in HCMECs exposed to doxorubicin showed a potential protective effect in contrast to enhanced toxicity to doxorubicin in A2780 ovarian cancer cells and BT474 breast cancer cells (Supplementary Figure S3 ).
One potential drawback to the clinical use of statins in reducing cardiac vascular permeability and reducing cardiotoxicity is the potential reduced delivery of chemotherapeutic agent to the tumor, reducing clinical efficacy. However, an in vivo study in mice using three different human tumor xenografts has shown that lovastatin potentiates doxorubicin anti-tumor activity while reducing doxorubicin-associated cardiotoxicity (Feleszko et al., 2000) . This would appear to back up our in vitro data. Furthermore, it is possible that statin mediated effects in potentially reducing tumor vascular permeability and delivery of drug to the tumor are ameliorated due to the inherent leakiness of tumor blood vessels compared with normal vasculature (Azzi, Hebda, & Gavard, 2013; De Bock et al., 2011) .
In summary, our data show that ERK5 regulates tight junction formation and permeability in cardiac microvascular endothelial cells.
Statin mediated ERK5 activation results in the translocation of ERK5 to the plasma membrane and regulation of tight junction formation and decreased endothelial cell permeability. Activation of ERK5 by drugs such as statins may have therapeutic potential in alleviating conditions where endothelial cell barrier formation is compromised such as druginduced cardiac injury (Wilkinson et al., 2016) , arterial hypertension (Laine, 1988) , sepsis (Rachoin, Cerceo, & Dellinger, 2013) , and diabetic nephropathy (Peng et al., 2013) .
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